{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T16:08:17Z","timestamp":1760890097069},"reference-count":22,"publisher":"American Institute of Mathematical Sciences (AIMS)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.3934\/mbe.2020261","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T08:08:34Z","timestamp":1594282114000},"page":"4773-4800","source":"Crossref","is-referenced-by-count":3,"title":["Design of personalized cancer treatments by use of optimal control problems: The case of chronic myeloid leukemia"],"prefix":"10.3934","volume":"17","author":[{"given":"Pedro","family":"Jos\u00e9 Guti\u00e9rrez-Diez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"1 Mathematics Research Institute of the University of Valladolid (IMUVa) and Faculty of Economics, University of Valladolid, Spain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"2 The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, USA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2321","reference":[{"key":"6","unstructured":"6. V. Volterra, <i>Le&#231;ons sur la th&#233;orie math&#233;matique de la lutte pour la vie<\/i>, Paris: Gauthier-Villars, 1931.","article-title":"V. Volterra, <i>Le&#231;ons sur la th&#233;orie math&#233;matique de la lutte pour la vie<\/i>,"},{"key":"10","unstructured":"10. Y. Koizumi, S. Iwami, Mathematical modeling of multi-drugs therapy: A challenge for determining the optimal combinations of antiviral drugs, <i>Theor. Biol. Med. Mod.<\/i>, 11 (2014), 41.","article-title":"Y. Koizumi, S. Iwami, Mathematical modeling of multi-drugs"},{"key":"12","unstructured":"12. J. D. Murray, <i>Mathematical Biology I: An Introduction<\/i>, Springer, 2002.","article-title":"J. D. Murray, <i>Mathematical Biology"},{"key":"13","unstructured":"13. J. D. Murray, <i>Mathematical Biology II: Spatial Models and Biomedical Applications<\/i>, Springer, 2003.","article-title":"J. D. Murray, <i>Mathematical Biology"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2013.06.009","article-title":"t al., Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic nich","author":"K. Schepers, E. M. Pietras, D. Reynaud, J. Flach, M. Binnewies, T. Garg","journal-title":"<i>Cell<\/i> <i>Stem Cell<\/i>"},{"key":"25","unstructured":"25. P. J. Guti&#233;rrez-Diez, M. &#193;.,L&#243;pez-Marcos, J. Mart&#237;nez-Rodr&#237;uez, J. Russo, The effects of time valuation in cancer optimal therapies: A study of chronic myeloid leukemia, <i>Theor. Biol. Med.<\/i> <i>Mod.<\/i>, 16 (2019), 10.","article-title":"P. J. Guti&#233;rrez-Diez, M. &#193;.,L&#243;pez-Marcos, J. Mart&#237;nez-Rodr&#237;uez, J. Russo, The effects of time valuation in cancer optimal"},{"key":"31","unstructured":"31. H. W. Sinn, Weber's law and the biological evolution of risk preferences: The selective dominance of the logarithmic utility function, <i>Gen. Pap. Risk Ins. Theor.<\/i>, 28 (2002), 87-100.","article-title":"H. W. Sinn, Weber's law and the biological evolution of risk"},{"key":"32","unstructured":"32. R. Capdeville, S. Silverman, Imatinib: A targeted clinical drug development, <i>Semin. Hematol.<\/i>, 40 (2003), 15-20.","article-title":"R. Capdeville, S. Silverman,"},{"key":"34","unstructured":"34. S. Soverini, A. Hochhaus, F. E. Nicolini, F. Gruber, T. Lange, G. Saglio, et al., BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet. <i>Blood<\/i>, 118 (2011), 1208-1215.","article-title":"S. Soverini, A. Hochhaus, F. E. Nicolini, F. Gruber, T. Lange, G. Saglio, et al., BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase"},{"key":"36","unstructured":"36. S. Prabhu, D. Saadat, M. Zhang, L. Halbur, J. P. Fruehauf, S. T. Ong, A novel mechanism for BCR-ABL action: BCR-ABL-mediated induction of the eIF4F translation initiation complex and mRNA translation, <i>Oncogene<\/i>, 26 (2007), 1188-1200.","article-title":"S. Prabhu, D. Saadat, M. Zhang, L. Halbur, J. P. Fruehauf, S. T. Ong, A novel mechanism for BCR-ABL"},{"key":"37","unstructured":"37. L. Hu, L. Pu, D. Yang, C. Zhang, H. Wang, Y. Ding, et al., How to detect the rare BCR-ABL (e14a3) transcript: A case report and literature review, <i>Oncol. Lett.<\/i>, 14 (2017), 5619-5623.","article-title":"L. Hu, L. Pu, D. Yang, C. Zhang, H. Wang, Y. Ding, et al., How to detect the rare BCR-ABL (e14a3)"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.168","article-title":"t al., BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phas","author":"T. Hughes, G. Saglio, A. Quint&#225;s-Cardama, M. J. Mauro, D. W. Kim, J. H. Lipton","journal-title":"<i>Leukemia<\/i>"},{"key":"40","unstructured":"40. J. Kaeda, D. O'Shea, R. M. Szydlo, E. Olavarria, F. Dazzi, D. Marin, et al., Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: An attempt to define patients who may not require further therapy, <i>Blood<\/i>, 107 (2006), 4171-4176.","article-title":"J. Kaeda, D. O'Shea, R. M. Szydlo, E. Olavarria, F. Dazzi, D. Marin, et al., Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid"},{"key":"44","unstructured":"44. R. Arora, R. D. Press, Measurement of BCR-ABL1 transcripts on the International Scale in the United States: Current status and best practices, <i>Leuk. Lymphoma<\/i>, 58 (2017), 8-16.","article-title":"R. Arora, R. D. Press, Measurement of BCR-ABL1 transcripts on the International Scale in the United"},{"key":"48","unstructured":"48. D. Raspadori, P. Pacelli, A. Sicuranza, E. Abruzzese, A. Iurlo, D. Cattaneo, et al., Flow Cytometry Assessment of CD26<sup>+<\/sup> Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia, <i>Cytometry Part B<\/i>, 96 (2019), 294-299.","article-title":"D. Raspadori, P. Pacelli, A. Sicuranza, E. Abruzzese, A. Iurlo, D. Cattaneo, et al., Flow Cytometry Assessment of CD26<sup>+<\/sup> Leukemic Stem Cells in Peripheral"},{"key":"55","unstructured":"55. M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, et al., Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet, <i>J. Clin. Oncol.<\/i>, 27 (2009), 6041-6051.","article-title":"M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, et al., Chronic myeloid"},{"key":"58","unstructured":"58. P. Valent, Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches, <i>Biol. Targets Ther.<\/i>, 1 (2007), 433-448.","article-title":"P. Valent, Imatinib-resistant chronic myeloid leukemia"},{"key":"60","unstructured":"60. T. R. Randolph, Myeloproliferative neoplasms, in <i>Rodak's Hematology Clinical Applications and<\/i> <i>Principles<\/i>, St. Louis, Missouri: Saunders, (2015), 561-590.","article-title":"T. R. Randolph, Myeloproliferative neoplasms, in <i>Rodak's Hematology Clinical Applications and<\/i> <i>Principles<\/i>, St. Louis,"},{"key":"64","unstructured":"64. M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, et al., Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net, <i>Blood<\/i>, 108 (2006), 1809-1820.","article-title":"M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, et al., Evolving concepts in the management of chronic myeloid"},{"key":"70","unstructured":"70. European Leukemia Net, 2020. Available from: https:\/\/www.leukemia-net.org\/content\/leukemias\/cml\/euro_and_sokal_score\/index_eng.html.","article-title":"European Leukemia Net, 2020. Available"},{"key":"73","unstructured":"73. J. Hasford, M. Baccarani, V. Hoffmann, J. Guilhot, S. Saussele, G. Rosti, et al., Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score, <i>Blood<\/i>, 118 (2011), 686-692.","article-title":"t al., Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scor"},{"key":"76","unstructured":"76. L.O. Ngolet, I. Kocko, A. Elira-Dokekias, Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country, <i>Case Rep. Hematol.<\/i>, (2016), 6104948.","article-title":"L.O. Ngolet, I. Kocko, A. Elira-Dokekias, Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with"}],"container-title":["Mathematical Biosciences and Engineering"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.aimspress.com\/article\/10.3934\/mbe.2020261\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T08:08:35Z","timestamp":1594282115000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aimspress.com\/article\/10.3934\/mbe.2020261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3934\/mbe.2020261","relation":{},"ISSN":["1551-0018"],"issn-type":[{"type":"print","value":"1551-0018"}],"subject":[],"published":{"date-parts":[[2020]]}}}